Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lintuzumab: Phase Ia data

In a multicenter, dose-escalation, single-arm Phase Ia trial in 17 evaluable AML

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE